tiprankstipranks
Trending News
More News >
Pascal Biosciences Inc (TSE:NEVI)
:NEVI
Advertisement

Pascal Biosciences Inc (NEVI) AI Stock Analysis

Compare
5 Followers

Top Page

TSE:NEVI

Pascal Biosciences Inc

(NEVI)

Select Model
Select Model
Select Model
Neutral 46 (OpenAI - 4o)
Rating:46Neutral
Price Target:
C$0.00
▼(-100.00% Downside)
The overall stock score of 46 reflects the company's gradual financial improvements and short-term technical momentum. However, significant challenges remain with profitability and valuation, as indicated by the negative P/E ratio and lack of dividend yield. Continued operational improvements and strategic financial management are essential for enhancing the stock's attractiveness.

Pascal Biosciences Inc (NEVI) vs. iShares MSCI Canada ETF (EWC)

Pascal Biosciences Inc Business Overview & Revenue Model

Company DescriptionNevis Brands Inc. develops and markets cannabis products in the United States. Its flagship brand is Major, a cannabis beverage. The company was formerly known as Pascal Biosciences Inc. and changed its name to Nevis Brands Inc. in June 2023. Nevis Brands Inc. is headquartered in Seattle, Washington.
How the Company Makes MoneyPascal Biosciences Inc generates revenue primarily through the development and commercialization of its drug candidates. The company seeks to monetize its proprietary technologies and compounds through partnerships and licensing agreements with larger pharmaceutical firms. These collaborations often involve milestone payments, research funding, and royalties on sales of successfully developed products. Additionally, Pascal may receive grants and funding from governmental and non-governmental organizations to support its research and development efforts. The company's revenue model is heavily reliant on successful drug development and strategic partnerships within the biotech and pharmaceutical industry.

Pascal Biosciences Inc Financial Statement Overview

Summary
Pascal Biosciences Inc is gradually improving its financial performance with growing revenues and positive operational cash flow. However, the company still faces significant challenges with profitability and historical negative equity. Continued focus on cost management and capital structure optimization will be crucial for sustainable growth.
Income Statement
45
Neutral
Pascal Biosciences Inc has shown a moderate improvement in revenue with a TTM revenue of $1,585,656, representing growth from previous periods. However, the company is still facing challenges in profitability with a negative net income of -$259,009. The gross profit margin stands at 61.8%, which is healthy, but the net profit margin is negative due to high operational expenses relative to revenue. EBITDA has turned positive in the TTM, indicating some operational improvement.
Balance Sheet
50
Neutral
The balance sheet shows a relatively stable position with total assets of $2,069,189 and stockholders' equity of $1,291,036. The debt-to-equity ratio is 0.36, indicating a reasonable level of leverage. Equity ratio at 62.4% reflects a solid capital structure. However, the company has a history of negative equity, which poses potential financial risks.
Cash Flow
40
Negative
Cash flow from operations is marginally positive at $14,507, signaling a slight recovery. Free cash flow is also positive at $26,962 in the TTM, showing improvement from previous years. However, the free cash flow to net income ratio is negative due to ongoing net losses, and reliance on financing is evident with a significant negative financing cash flow.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.57M1.55M671.54K0.000.000.00
Gross Profit1.18M1.08M392.94K-8.29K-16.32K-12.48K
EBITDA103.62K-48.07K-266.92K-468.09K-1.07M-1.22M
Net Income-205.76K-362.48K-399.77K-480.28K-1.09M-1.24M
Balance Sheet
Total Assets1.94M2.04M2.50M18.82K155.19K120.71K
Cash, Cash Equivalents and Short-Term Investments53.63K129.54K418.52K8.37K0.000.00
Total Debt459.74K528.30K683.27K224.62K7.76K16.91K
Total Liabilities733.93K813.50K1.12M962.93K646.48K473.05K
Stockholders Equity1.21M1.23M1.38M-944.11K-491.30K-352.34K
Cash Flow
Free Cash Flow9.55K-132.06K-390.49K-147.68K-614.93K-862.83K
Operating Cash Flow9.55K-120.50K-385.35K-147.68K-614.93K-862.83K
Investing Cash Flow87.56K-11.56K-947.71K8.98K0.000.00
Financing Cash Flow-143.29K-167.65K1.76M154.84K624.08K471.07K

Pascal Biosciences Inc Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.08
Price Trends
50DMA
0.06
Positive
100DMA
0.06
Positive
200DMA
0.07
Positive
Market Momentum
MACD
<0.01
Negative
RSI
64.37
Neutral
STOCH
65.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NEVI, the sentiment is Positive. The current price of 0.08 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.06, and above the 200-day MA of 0.07, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 64.37 is Neutral, neither overbought nor oversold. The STOCH value of 65.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:NEVI.

Pascal Biosciences Inc Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
46
Neutral
C$3.17M-16.65%5.31%41.57%
44
Neutral
C$1.79M-69.77%-15.51%-49.26%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:NEVI
Pascal Biosciences Inc
0.08
-0.02
-20.00%
TSE:GENX
Genix Pharmaceuticals
0.03
-0.02
-40.00%
TSE:CBP
Certive Solutions
0.01
0.00
0.00%
TSE:NLV
New Leaf Ventures
0.05
0.00
0.00%
TSE:RAMM
Ramm Pharma
0.02
0.00
0.00%
TSE:FLOW
Flow Beverage Corp.
0.04
-0.15
-78.95%

Pascal Biosciences Inc Corporate Events

Business Operations and StrategyShareholder Meetings
Nevis Brands Inc. Secures Strong Shareholder Support at AGM
Positive
Aug 28, 2025

Nevis Brands Inc. announced the successful approval of all matters at its Annual General Meeting, reflecting strong shareholder support. The meeting, held in Vancouver, saw nearly 14% of eligible shares voted, with resolutions such as the election of directors and appointment of an auditor receiving overwhelming approval. This outcome underscores the confidence shareholders have in the company’s leadership and strategic direction, potentially strengthening its position in the cannabis beverage market.

Business Operations and StrategyProduct-Related Announcements
Nevis Brands Expands Major™ Cannabis Beverages to New Mexico
Positive
Aug 27, 2025

Nevis Brands Inc. has announced a licensing agreement with Stash House NM to produce and distribute its Major™ cannabis beverages in New Mexico, marking a significant expansion into the Southwest’s rapidly growing cannabis market. This move is expected to enhance Nevis’s market presence and capitalize on New Mexico’s burgeoning cannabis industry, which saw over $800 million in sales in 2024, and aligns with the company’s broader strategy of expanding its footprint across multiple states.

Business Operations and StrategyProduct-Related Announcements
Nevis Brands Expands Midwest Reach with Strategic Distribution Agreement
Positive
Jul 16, 2025

Nevis Brands Inc. has announced a strategic distribution agreement with Z.T. Distribution Inc. to expand the reach of its hemp-derived THC beverage, Happy Apple™, in Wisconsin, Minnesota, and Illinois. This partnership with ZT, a well-established distributor, is expected to enhance Nevis Brands’ market penetration and capitalize on the growing demand for hemp-derived beverages, aligning with the company’s strategy to broaden its footprint in the U.S. market.

Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Nevis Brands Sees Revenue Growth Amid New Product Launches
Neutral
Jul 14, 2025

Nevis Brands Inc. reported a slight increase in revenue for Q2 2025, driven by stable performance in its licensed markets and the introduction of its hemp-derived THC product line. Despite stable gross margins, the company faced a net loss due to foreign exchange pressures and elevated audit costs. Nevis continues to expand geographically, with growth in New Jersey and Missouri, and anticipates increased sales from its new hemp-derived THC beverage. The company’s asset-light licensing model supports high margins and adaptability to regulatory changes, positioning it for growth as the cannabis beverage market matures.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 26, 2025